PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Colistimethate sodium - Cystic fibrosis
PAD Profile : Colistimethate sodium - Cystic fibrosis
Keywords :
NICE
Brand Names Include :
Colistin, Colomycin, Promixin
Traffic Light Status
Status 1 of 1.
Status :
Red
Important
Formulations :
- Inhalation
Important Information :
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
- Aztreonam
- Dornase alfa
- Ivacaftor
- Tobramycin
- Levofloxacin
- Amikacin
- Amikacin liposomal
- Ciprofloxacin
- Ciprofloxacin liposomal
- Lumacaftor with ivacaftor
- Mannitol
- Antipseudomonas aeruginosa IgY
- Tezacaftor with ivacaftor
- Ivacaftor with tezacaftor and elexacaftor
Other Indications
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
01 May 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Implementation of NICE TA276 - No action required Colistimethate for Cystic Fibrosis is funded by NHS England from 1st April 2013
01 April 2013
Not Set
FOR NEW PATIENTS ONLY. Prescribing of Colistimethate Sodium will be considered RED on the Prescribing Advisory database. Historically amber for CF patients via nebulisation / inhalation.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Associated BNF Codes
05. Infections
05.01.07. Some other antibacterials